🐂 Not all bull runs are created equal. November’s AI picks include 5 stocks up +20% eachUnlock Stocks

Corcept Therapeutics Incorporated (CORT)

NASDAQ
Currency in USD
56.45
-1.34(-2.32%)
Closed
After Hours
57.74+1.29(+2.29%)
CORT Scorecard
Full Analysis
2 analysts have revised their earnings upwards for the upcoming period
Fair Value
Day's Range
56.4159.26
52 wk Range
20.8461.66
Key Statistics
Edit
Prev. Close
56.45
Open
58.02
Day's Range
56.41-59.26
52 wk Range
20.84-61.66
Volume
581,496
Average Volume (3m)
917,898
1-Year Change
121.89%
Book Value / Share
unlockUnlock
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
CORT Scorecardpro icon
Company’s Health
pro lockUnlock
Fair Value
pro lockUnlock Price
Fair Pricepro lock
Upsidepro lock
Price Target
74.90
Upside
+32.68%
Members' Sentiments
Bearish
Bullish
ProTips
Trading at a low P/E ratio relative to near-term earnings growth
Show more

Corcept Therapeutics Incorporated Company Profile

Corcept Therapeutics Incorporated engages in discovery and development of drugs for the treatment of severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States. It offers Korlym tablets medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous cushing’s syndrome; and who have type 2 diabetes mellitus or glucose intolerance and have failed surgery or are not candidates for surgery. The company is also developing relacorilant, which is in phase III clinical trial for the treatment of cushing’s syndrome; treatment for adrenal cancer and cortisol excess which is in phase 1b clinical trial; treatment for prostate cancer which is in phase II clinical trial; and nab-paclitaxel in combination with relacorilant, which is in phase III clinical trial to treat platinum-resistant ovarian tumors. In addition, it develops dazucorilant, which is in phase II clinical trial for the treatment of amyotrophic lateral sclerosis; miricorilant, which is in phase IIb trial for the treatment of nonalcoholic steatohepatitis; and treatment for antipsychotic induced weight gain that is in phase I trial. The company was incorporated in 1998 and is headquartered in Menlo Park, California.

Employees
352

Compare CORT to Peers and Sector

Metrics to compare
CORT
Peers
Sector
Relationship
P/E Ratio
42.1x−0.3x−0.7x
PEG Ratio
0.740.000.00
Price/Book
9.3x−0.1x2.6x
Price / LTM Sales
9.4x2.5x3.2x
Upside (Analyst Target)
31.5%100.4%47.0%
Fair Value Upside
Unlock21.7%8.3%Unlock

People Also Watch

79.76
LNTH
-6.33%
162.43
FTAI
+0.61%
446.28
FIX
-3.62%
47.790
VIST
+0.25%
104.35
MMYT
+0.14%

FAQ

What Is the Corcept (CORT) Stock Price Today?

The Corcept stock price today is 56.45

What Stock Exchange Does Corcept Trade On?

Corcept is listed and trades on the NASDAQ stock exchange.

What Is the Stock Symbol for Corcept?

The stock symbol for Corcept is "CORT."

What Is the Corcept Market Cap?

As of today, Corcept market cap is 5.91B.

What is Corcept Earnings Per Share?

The Corcept EPS is 1.36.

What Is the Next Corcept Earnings Date?

Corcept will release its next earnings report on Feb 12, 2025.

From a Technical Analysis Perspective, Is CORT a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.